{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Symptom+Clusters&page=96",
    "query": {
      "condition": "Symptom Clusters",
      "page": 96
    },
    "page_size": 10
  },
  "pagination": {
    "page": 96,
    "page_size": 10,
    "total_count": 16859,
    "total_pages": 1686,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Symptom+Clusters&page=97&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Symptom+Clusters&page=95&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-13T00:36:58.949Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05521958",
      "title": "Gene Expression in Lower Extremity Acute Traumatic Compartment Syndrome",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Tibial Shaft Fracture",
        "Tibial Plateau Fracture"
      ],
      "interventions": [
        {
          "name": "Acute injury without compartment syndrome",
          "type": "PROCEDURE"
        },
        {
          "name": "Acute injury with compartment syndrome",
          "type": "PROCEDURE"
        },
        {
          "name": "Exertional compartment syndrome",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 80,
      "start_date": "2022-06-10",
      "completion_date": "2028-06",
      "has_results": false,
      "last_update_posted_date": "2026-04-29",
      "last_synced_at": "2026-11-13T00:36:58.949Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05521958"
    },
    {
      "nct_id": "NCT00099684",
      "title": "Safety, Effectiveness, and Tolerability of Ezetimibe Combined With Statins for the Treatment of High Cholesterol in HIV Infected Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Ezetimibe",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 44,
      "start_date": "2005-11",
      "completion_date": "2007-05",
      "has_results": false,
      "last_update_posted_date": "2012-10-29",
      "last_synced_at": "2026-11-13T00:36:58.949Z",
      "location_count": 41,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • San Diego, California + 24 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00099684"
    },
    {
      "nct_id": "NCT06639984",
      "title": "Psyllium in Pediatric IBS",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Irritable Bowel Syndrome"
      ],
      "interventions": [
        {
          "name": "Psyllium (0.7 g/year of age per day)",
          "type": "DRUG"
        },
        {
          "name": "Psyllium (0.5 g/year of age per day)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "fructans",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Dr Bruno Chumpitazi, M.D.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "12 Years to 17 Years"
      },
      "enrollment_count": 110,
      "start_date": "2025-02-20",
      "completion_date": "2027-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-05-26",
      "last_synced_at": "2026-11-13T00:36:58.949Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06639984"
    },
    {
      "nct_id": "NCT00341484",
      "title": "Genetic Susceptibility to Oncogenic Viruses",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Liver Neoplasms",
        "HIV Infections"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 2580,
      "start_date": "1998-06-01",
      "completion_date": "2007-06-05",
      "has_results": false,
      "last_update_posted_date": "2020-06-16",
      "last_synced_at": "2026-11-13T00:36:58.949Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00341484"
    },
    {
      "nct_id": "NCT00002248",
      "title": "A Randomized, Multicenter, Double-Blind, Parallel-Group, Placebo-Controlled Trial of the Efficacy and Safety of Bovine Anti-Cryptosporidium Immunoglobulin (BACI) in the Treatment of Cryptosporidium Enteritis in AIDS Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cryptosporidiosis",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Cryptosporidium Immune Whey Protein Concentrate (Bovine)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Univax Biologics Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2005-06-24",
      "last_synced_at": "2026-11-13T00:36:58.949Z",
      "location_count": 6,
      "location_summary": "Los Angeles, California • San Francisco, California • Atlanta, Georgia + 2 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002248"
    },
    {
      "nct_id": "NCT00509249",
      "title": "Aflibercept in Treating Patients With Myelodysplastic Syndromes",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative",
        "Chronic Myelomonocytic Leukemia",
        "de Novo Myelodysplastic Syndromes",
        "Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable",
        "Previously Treated Myelodysplastic Syndromes",
        "Secondary Myelodysplastic Syndromes"
      ],
      "interventions": [
        {
          "name": "ziv-aflibercept",
          "type": "BIOLOGICAL"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2007-09",
      "completion_date": "2010-12",
      "has_results": true,
      "last_update_posted_date": "2015-01-08",
      "last_synced_at": "2026-11-13T00:36:58.949Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00509249"
    },
    {
      "nct_id": "NCT02508038",
      "title": "Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Acute Lymphoblastic Leukemia",
        "Hodgkin Lymphoma",
        "Non-Hodgkin Lymphoma",
        "Myelodysplastic Syndrome",
        "Myeloproliferative Syndrome",
        "Rhabdomyosarcoma",
        "Ewing Sarcoma",
        "Primitive Neuroectodermal Tumor",
        "Osteosarcoma",
        "Neuroblastoma"
      ],
      "interventions": [
        {
          "name": "TCRαβ+/CD19+ depleted Haploidentical HSCT",
          "type": "PROCEDURE"
        },
        {
          "name": "Zoledronate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "University of Wisconsin, Madison",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "7 Months",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "7 Months to 21 Years"
      },
      "enrollment_count": 22,
      "start_date": "2016-02-12",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2026-10-27",
      "last_synced_at": "2026-11-13T00:36:58.949Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02508038"
    },
    {
      "nct_id": "NCT07360938",
      "title": "Drug Interaction Potential of Pro-Inflammatory Conditions",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Diabetes Mellitus, Type 2",
        "End Stage Renal Disease",
        "Irritable Bowel Syndrome"
      ],
      "interventions": [
        {
          "name": "None (Observational)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Indiana University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "12 Years to 99 Years"
      },
      "enrollment_count": 150,
      "start_date": "2025-11-01",
      "completion_date": "2030-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-01-22",
      "last_synced_at": "2026-11-13T00:36:58.949Z",
      "location_count": 1,
      "location_summary": "Indianapolis, Indiana",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07360938"
    },
    {
      "nct_id": "NCT06430385",
      "title": "ATTUNE: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally-Administered ION440 in Participants With Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome (MDS)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome"
      ],
      "interventions": [
        {
          "name": "ION440",
          "type": "DRUG"
        },
        {
          "name": "Sham procedure",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Ionis Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "65 Years",
        "sex": "MALE",
        "summary": "2 Years to 65 Years · Male only"
      },
      "enrollment_count": 48,
      "start_date": "2024-10-21",
      "completion_date": "2030-04",
      "has_results": false,
      "last_update_posted_date": "2026-10-08",
      "last_synced_at": "2026-11-13T00:36:58.949Z",
      "location_count": 8,
      "location_summary": "San Diego, California • Aurora, Colorado • Baltimore, Maryland + 5 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Saint Paul",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06430385"
    },
    {
      "nct_id": "NCT04732949",
      "title": "Study to Assess Efficacy and Safety of Inhaled Interferon-β Therapy for COVID-19",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Severe Acute Respiratory Syndrome Coronavirus 2",
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "SNG001",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Synairgen Research Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 623,
      "start_date": "2021-01-12",
      "completion_date": "2022-02-10",
      "has_results": true,
      "last_update_posted_date": "2023-03-27",
      "last_synced_at": "2026-11-13T00:36:58.949Z",
      "location_count": 6,
      "location_summary": "Tucson, Arizona • St. Petersburg, Florida • Detroit, Michigan + 3 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04732949"
    }
  ]
}